

FRED UPTON, MICHIGAN  
CHAIRMAN

HENRY A. WAXMAN, CALIFORNIA  
RANKING MEMBER

ONE HUNDRED THIRTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115  
Majority (202) 225-2927  
Minority (202) 225-3641

June 5, 2013

Ms. Elizabeth Gallenagh  
Vice President of Government Affairs and  
General Counsel  
Healthcare Distribution Management Association  
901 North Glebe Road, Suite 1000  
Arlington, VA 22203

Dear Ms. Gallenagh:


Thank you for appearing before the Subcommittee on Health on Thursday, April 25, 2013, to testify at the hearing entitled "Securing Our Nation's Prescription Drug Supply Chain."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions by the close of business on Wednesday, June 19, 2013. Your responses should be e-mailed to the Legislative Clerk in Word format at [Sydne.Harwick@mail.house.gov](mailto:Sydne.Harwick@mail.house.gov) and mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

  
Joseph R. Pitts  
Chairman  
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

## Attachment 1—Additional Questions for the Record

### The Honorable John D. Dingell

1. Do you agree that a traceability system would help to better secure our drug supply chain from counterfeits, theft, and intentional adulteration? If no, please explain why.
2. Do you agree that a traceability system would help to identify and detect illegitimate pharmaceuticals? If no, please explain why.
3. Do you agree that a traceability system would help to ensure the safety of pharmaceuticals for patients and consumers? If no, please explain why.
4. Do you agree that a traceability system would improve the efficiency and effectiveness of recalls or returns? If no, please explain why.
5. Do you agree that a federal traceability system should be based on uniform, national standards? If no, please explain why.
6. Do you agree that a federal traceability system should include participation from everyone in the supply chain? Please explain why.
7. Do you agree that a federal traceability system should take a phased-in approach? If no, please explain why.
8. Do you agree that a federal traceability system with a phased-in approach should include clear requirements and a clear timeframe for a second phase? If no, please explain why.
9. Do you believe that a unit level traceability system is feasible at this time for all members of your industry? Please explain why.
10. Do you believe that a lot level traceability system is feasible at this time for all members of your industry? Please explain why.
11. Do you agree that the goal of any federal traceability system should be unit level tracing? If no, please explain why.
12. Do you believe that it is imperative that traceability legislation be passed this year? If no, please explain why.